Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study

Authors: Joel W. Neal, MD, PhD, Armando Santoro, MD, Maria Gonzalez-Cao, MD, PhD, Farah Louise Lim, MRCP, MD, Bruno Fang, MD, Ryan D. Gentzler, MD, MS, Jerome Goldschmidt, MD, Polina Khrizman, MD, Claudia Proto, MD, Shiven Patel, MD, MBA, FACP, Sonam Puri, MD, Stephen V. Liu, MD, Erminia Massarelli, MD, PhD, MS, Denise Williamson, MPH, Martin Schwickart, PhD, Christian Scheffold, MD, PhD, Svetlana Andrianova, MD, MPH, Enriqueta Felip, MD, PhD

Source: JTO Clinical and Research Reports, Vol 5, Iss 10, Pp 100666- (2024)

Subject Terms: Cabozantinib, Atezolizumab, Non–small cell lung cancer, Immunotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324000365; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/6812448f29344fa6a786793805d199c0

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential

Authors: Natalie J. Tigue, Lisa Bamber, John Andrews, Samantha Ireland, James Hair, Edward Carter, Sudharsan Sridharan, Jelena Jovanović, D. Gareth Rees, Jeremy S. Springall, Emilie Solier, Yi-Ming Li, Matthieu Chodorge, David Perez-Martinez, Daniel R. Higazi, Michael Oberst, Maureen Kennedy, Chelsea M. Black, Li Yan, Martin Schwickart, Shaun Maguire, Jennifer A. Cann, Lolke de Haan, Lesley L. Young, Tristan Vaughan, Robert W. Wilkinson, Ross Stewart

Source: OncoImmunology, Vol 6, Iss 3 (2017)

Subject Terms: agonist, gitr, gitrl, hexamer, medi1873, t cell, tumor, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2162-402X

Access URL: https://doaj.org/article/2ce1d1f11ec645bc9ff9055a90e162ac